Comparison of survival outcomes for people with HR+/HER2− metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary Authors: Hope S Rugo, Rachel M Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Published: 2026 ABSTRACT Plain Language Summary What is this summary about? This summary describes two original articles from one study that compared health outcomes for people with metastatic breast cancer. The people in the study received one of three different medicines called CDK4/6 inhibitors: palbociclib, ribociclib, or abemaciclib, in combination with an aromatase inhibitor, as their first treatment following a metastatic breast cancer diagnosis. There has never been a clinical trial that directly compares how well these three CDK4/6 inhibitors work for people with metastatic breast cancer. The researchers wanted to know if any of the three medicines, when combined with an aromatase inhibitor, were associated with A) a longer period of time that people’s cancer remained under control after starting treatment or B) longer life for people in the study. The study used information from a large database that contained the medical records of people treated in cancer clinics in the United States. Only people with HR+/HER2− metastatic breast cancer were included in the study. What were the results? Among the three medicines taken in combination with an aromatase inhibitor, there were no significant differences in how long it took for people’s cancer to get worse. There were also no significant differences in how long people lived after starting any of the three medicines with an aromatase inhibitor. What do the results mean? These results support the use of palbociclib, ribociclib, or abemaciclib in combination with an aromatase inhibitor as a first treatment for people with HR+/HER2− metastatic breast cancer.Clinical trial number: NCT06495164KEYWORDS: abemaciclib, aromatase inhibitor, comparative effectiveness, cyclin-dependent kinase 4/6 inhibitor, hormone therapy, palbociclib, plain language summary, real-world study, ribociclib Acknowledgments The authors would like to thank all the people who contributed to the information used in this study. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text Link to original article here Link to original article here Disclosure statement Hope S. Rugo reported a consulting or advisory role for Napo, Bristol Myers Squibb, Helsinn, and BioNTech; institutional research funding to her prior institution (UCSF) from AstraZeneca, Gilead Sciences Inc., Lilly, Merck & Co., Daiichi-Sankyo Inc., Novartis Pharmaceuticals, Pfizer Inc, F. Hoffman-La Roche/AG/Genentech, Stemline Therapeutics, and Ambryx; and institutional research funding to City of Hope from Bicycle Therapeutics, F. Hoffman-La Roche/AG/Genentech, Merck, PhoenixMD, and Stemline Therapeutics. Rachel M. Layman reported receiving advisory/consultancy fees from Novartis, Eli Lilly, Gilead Sciences, Biotheryx and Celcuity; honorarium provided by Pfizer; institutional research support from Pfizer Inc, Novartis, Eli Lilly, Puma, Celcuity, Accutar Biotechnology, Arvinas, and Biotheryx. Filipa Lynce reported a consulting or advisory role for AstraZeneca, Daiichi-Sankyo/Astra Zeneca, OncoSec, AmerisourceBergen, Pfizer, and Prime Education; research funding from Bristol Myers Squibb, Immunomedics (Inst), Inivata (Inst), AstraZeneca/Daiichi-Sankyo (Inst), and CytomX Therapeutics (Inst). Xianchen Liu reported employment from, and stockholder in, Pfizer Inc. Benjamin Li reported employment from, and stockholder in, Pfizer Inc. Lynn McRoy reported employment from, and stockholder in, Pfizer Inc. Aaron B. Cohen reported employment from Flatiron Health, which received funding from Pfizer in connection with the development of this plain language summary, and being a stockholder in Roche. Melissa Estevez reported employment from Flatiron Health, which received funding from Pfizer in connection with the development of this plain language summary, and being a stockholder in Roche. Giuseppe Curigliano reported receiving honoraria from Ellipses Pharma; consulting or advisory role for Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boehringer Ingelheim, GlaxoSmithKline, Seagen, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, and Merck; speakers’ bureau for Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi-Sankyo, Seagen, and Menarini; research funding from Merck (Inst); and travel, accommodations, and expenses from Roche/ Genentech, Pfizer, and Daiichi-Sankyo. Adam Brufsky reported receiving grants from Agendia and AstraZeneca; consulting fees or honoraria from AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, Seagen, Daiichi-Sankyo, Merck, Agendia, Sanofi, and Puma. The authors have no other competing interests or financial involvement with any organization or entity with a financial interest or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by Kevin Woolfrey, PhD, of Oxford PharmaGenesis Inc., Wilmington, DE, USA, and was funded by Pfizer Inc. Reviewer disclosures Patient reviewers on this PLSP have received honorarium from Future Oncology for their review work but have no other relevant financial relationships to disclose. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Funding This manuscript was funded by Pfizer Inc. Pfizer employees participated in study design, data analysis, and decisions to publish the studies summarized in this manuscript.